OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research report report published on Wednesday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Price Performance

OPGN stock opened at $0.41 on Wednesday. The stock has a market capitalization of $5.16 million, a P/E ratio of -0.06 and a beta of -0.71. OpGen has a 1-year low of $0.17 and a 1-year high of $3.84. The business has a fifty day moving average price of $0.57 and a 200-day moving average price of $0.51.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.